GlassScriptPhysician profile
Ketki P Mougey
NPI 1871671024
$9,667.40
in general payments reported to CMS, 2019-2025
47 companies · $909 in 2025
The $909 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,494 · 2020: $1,132 · 2021: $1,752 · 2022: $997 · 2023: $1,160 · 2024: $1,224 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,236.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $871.03 | 2019-2025 | Evenity |
| Novo Nordisk INC | $867.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $842.31 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $679.97 | 2019-2021 | |
| Pfizer INC. | $529.11 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $277.87 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.73 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $210.09 | 2020-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $205.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $205.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.63 | 2019-2023 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $176.34 | 2019-2025 | Gardasil 9, Vaxneuvance, Proquad |
| Dermira, INC. | $155.28 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketki Mougey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.